AdipoGen Life Sciences

ACY-775

As low as CHF 50.00

In stock

Only %1 left

AG-CR1-3903-M0011 mgCHF 50.00

AG-CR1-3903-M0055 mgCHF 150.00

Specifications / Handling

More Information
Product Details
Synonyms	2-((1-(3-Fluorophenyl)cyclohexyl)amino)-N-hydroxypyrimidine-5-carboxamide
Product Type	Chemical
Properties
Formula	C₁₇H₁₉FN₄O₂
MW	330.4
CAS	1375466-18-4
Purity Chemicals	≥95% (HPLC)
Appearance	Off white solid.
Solubility	Soluble in DMSO, methanol or ethanol.
Identity	Determined by ¹H-NMR.
InChi Key	IYBURCQQEUNLDL-UHFFFAOYSA-N
Smiles	ONC(=O)C1=CN=C(NC2(CCCCC2)C2=CC(F)=CC=C2)N=C1
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Keep cool and dry. Protect from light.
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product Description

Cell permeable, potent and selective class IIb HDAC6 inhibitor (IC₅₀ =7.5nM). Displays high selectivity over HDAC1-9 (IC₅₀=1-10µM).
Shows improved brain bioavailability compared to tubastatin A (Prod. No. AG-CR1-3900).
Induces hyperacetylation of α-tubulin in brain without concurrently altering the acetylation of histones.
Shows antidepressant activity.
HDAC6 deacetylates tubulin, HSP90 and the core histones (H2A, H2B, H3, H4). Histone deacetylases act via the formation of large multiprotein complexes. HDAC6 plays an important role in microtubule-dependent cell motility, transcriptional regulation, degradation of misfolded proteins and cell cycle and is involved in autophagy, inflammation, cancer and neurodegeneration.

Product-specific References

Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC: S. Mithraprabhu, et al.; Br. J. Haematol. 162, 559 (2013)
Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer: J.S. Riley, et al.; Cell Death Dis. 4, e951 (2013)
RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth: K.A. Wilson-Edell, et al.; Oncotarget 5, 5165 (2014)
Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability: J. Jochems, et al.; Neuropsychopharmacol. 39, 389 (2014)

Call	+41 61 926 6040
Fax	+41 61 926 6049